Neovasc Inc. Other financial activities

Other financial activities of NVCN for past 10 years: annual, quarterly and twelve month trailing (TTM) including Other financial activities growth rates and interactive chart.


Highlights and Quick Summary

  • Other financial activities for the quarter ending March 31, 2022 was $-291 Thousand (a 75.73% increase compared to previous quarter)
  • Year-over-year quarterly Other financial activities decreased by -111.64%
  • Annual Other financial activities for 2021 was $1.26 Million (a 33.89% increase from previous year)
  • Annual Other financial activities for 2020 was $941 Thousand (a -89.39% decrease from previous year)
  • Annual Other financial activities for 2019 was $8.87 Million (a -88.89% decrease from previous year)
  • Twelve month Other financial activities ending March 31, 2022 was $5.09 Million (a 295.76% increase compared to previous quarter)
  • Twelve month trailing Other financial activities decreased by -243.81% year-over-year
Trailing Other financial activities for the last four month:
31 Mar '22 31 Dec '21 30 Sep '21 30 Jun '21
$5.09 Million $1.29 Million $-892 Thousand $-3.54 Million
Visit stockrow.com/NVCN for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Other financial activities of Neovasc Inc.

Most recent Other financial activitiesof NVCN including historical data for past 10 years.

Interactive Chart of Other financial activities of Neovasc Inc.

Neovasc Inc. Other financial activities for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2022 $-0.29
2021 $-0.17 $3.05 $2.5 $-4.1 $1.26
2020 $-2.34 $0.4 $-0.58 $-1.75 $0.94
2019 $3.32 $8.87
2018 $79.81
2017 $65.33 $63.5
2016 $47.47
2014 $22.8
2012 $0.0 $0.04 $0.0 $0.04
2011 $0.01 $0.01

Business Profile of Neovasc Inc.

Sector: Healthcare
Industry: Medical Devices
Neovasc Inc., a specialty medical device company, develops, manufactures, and markets products for cardiovascular marketplace in Europe and internationally. Its products include the Tiara technology for the transcatheter treatment of mitral valve disease; and the Neovasc Reducer for the treatment of refractory angina. The company was formerly known as Medical Ventures Corp. and changed its name to Neovasc Inc. in July 2008. Neovasc Inc. was incorporated in 2000 and is headquartered in Richmond, Canada.